Listing 1 - 5 of 5 |
Sort by
|
Choose an application
Cancer --- Therapeutics, Experimental --- Drugs, Investigational --- Neoplasms --- Treatment --- therapeutic use --- drug therapy --- therapy --- Therapeutics, Experimental. --- therapeutic use. --- drug therapy. --- therapy. --- Treatment. --- Oncology. --- Experimental therapeutics --- Cancers --- Carcinoma --- Malignancy (Cancer) --- Malignant tumors --- Therapy --- Medicine, Experimental --- Tumors --- Thérapeutique expérimentale --- Traitement
Choose an application
Immunology. Immunopathology --- Allergy --- Immunology --- Therapeutics, Experimental --- Allergy and Immunology. --- Therapeutics. --- Immunology. --- Therapeutics, Experimental. --- Agriculture Sciences --- Health Sciences --- Soil Chemistry, Microbiology, Fertility & Fertilizers --- Therapeutics --- Experimental therapeutics --- Medicine, Experimental --- Therapy --- Treatment --- Therapeutic --- Therapies --- Treatments --- Disease --- Allergy Specialty --- Allergy, Immunology --- Immunology and Allergy --- Immunology, Allergy --- Specialty, Allergy --- therapy --- Immunobiology --- Life sciences --- Serology --- allergieën
Choose an application
Geriatric pharmacology. --- Drug delivery systems. --- Therapeutics, Experimental. --- Drug Delivery Systems. --- Aging --- Life Expectancy. --- Geriatrics --- physiology. --- methods. --- Life Extension --- Years of Potential Life Lost --- Expectancies, Life --- Expectancy, Life --- Life Expectancies --- Longevity --- Mortality, Premature --- Drug Targeting --- Delivery System, Drug --- Delivery Systems, Drug --- Drug Delivery System --- Drug Targetings --- System, Drug Delivery --- Systems, Drug Delivery --- Targeting, Drug --- Targetings, Drug --- Dosage Forms --- Experimental therapeutics --- Medicine, Experimental --- Delivery systems, Drug --- Drug administration technology --- Drug delivery technology --- Drugs --- Pharmaceutical technology --- Pharmacology --- Delivery systems
Choose an application
Genomics is majorly impacting therapeutics development in medicine. This book contains up-to-date information on the use of genomics in the design and analysis of therapeutic clinical trials with a focus on novel approaches that provide a reliable basis for identifying which patients are most likely to benefit from each treatment. It is oriented to both clinical investigators and statisticians. For clinical investigators, it includes background information on clinical trial design and statistical analysis. For statisticians and others who want to go deeper, it covers state-of-the-art adaptive designs and the development and validation of probabilistic classifiers. The author describes the development and validation of prognostic and predictive biomarkers and their integration into clinical trials that establish their clinical utility for informing treatment decisions for future patients.
Biomarkers, Tumor --- Neoplasms --- Precision Medicine --- Research Design --- Data Adjustment --- Data Reporting --- Design, Experimental --- Designs, Experimental --- Error Sources --- Experimental Designs --- Matched Groups --- Methodology, Research --- Problem Formulation --- Research Methodology --- Research Proposal --- Research Strategy --- Research Technics --- Research Techniques --- Scoring Methods --- Experimental Design --- Adjustment, Data --- Adjustments, Data --- Data Adjustments --- Design, Research --- Designs, Research --- Error Source --- Formulation, Problem --- Formulations, Problem --- Group, Matched --- Groups, Matched --- Matched Group --- Method, Scoring --- Methods, Scoring --- Problem Formulations --- Proposal, Research --- Proposals, Research --- Reporting, Data --- Research Designs --- Research Proposals --- Research Strategies --- Research Technic --- Research Technique --- Scoring Method --- Source, Error --- Sources, Error --- Strategies, Research --- Strategy, Research --- Technic, Research --- Technics, Research --- Technique, Research --- Techniques, Research --- Research --- Clinical Trials Data Monitoring Committees --- genetics --- methods --- Genomics --- Clinical trials. --- Medicine, Preventive. --- Disease prevention --- Diseases --- Prevention of disease --- Preventive medicine --- Pathology --- Preventive health services --- Preventive medicine physicians --- Public health --- Controlled clinical trials --- Patient trials of new treatments --- Randomized clinical trials --- Trials, Clinical --- Clinical medicine --- Human experimentation in medicine --- Genome research --- Genomes --- Molecular genetics --- Statistical methods. --- Prevention --- Clinical trials --- Tumor markers --- Therapeutics, Experimental --- Experimental therapeutics --- Medicine, Experimental --- Biological markers (Oncology) --- Cancer markers --- Markers, Tumor --- Tumor associated markers --- Biochemical markers --- Tumors
Choose an application
Recent years have seen the idea of a close association between nutrition and the modulation of cancer development/progression reinforced. An increasing amount of experimental and epidemiological evidence has been produced supporting the concept that many different bioactive components of food (e.g. polyphenols, mono- and polyunsaturated fatty acids, methyl-group donors, etc.) may be implicated in either the promotion of or the protection against carcinogenesis. At the cellular level, such compounds can have an impact on different but sometimes intertwined processes, such as growth and differentiation, DNA repair, programmed cell death, and oxidative stress. In addition, compelling evidence is starting to build up of the existence of primary epigenetic targets of dietary compounds, such as oncogenic/oncosuppressor miRNAs or DNA-modifying enzymes, which in turn impair gene expression and function. Since there is a growing interest in the study of the biochemical and molecular role played by food components and its impact on cellular processes and/or gene expressions directed towards the fine-tuning of cancer phenotypes, in this Special Issue researchers contributed with either research or review articles presenting the latest findings on the intracellular pathways and mechanisms affected by natural bioactive dietary molecules.
berberine --- signaling pathways --- oncogenic cascades --- TRAIL --- microRNAs --- cancer therapy --- colon cancer cells --- ethanol --- Nrf2 --- HO-1 --- ER stress --- autophagy --- MMPs --- formononetin --- cancer --- preclinical models --- cell signaling --- angiogenesis --- nobiletin --- colorectal cancer --- chemoprevention --- bioactivities --- experimental therapeutics --- HDAC --- multiple myeloma --- oleacein --- breast cancer --- persistent organic pollutants --- breast cancer risk --- breast cancer prognostic --- systematic review --- carrageenan --- invasion --- metastasis --- RacGAP1 --- radiotherapy --- marine sponge --- natural product --- anticancer drug --- oral cancer inhibition --- phytochemicals --- small organic agents --- Piper eriopodon, alkenylphenols --- human cancer cells --- cell death --- apoptosis --- caspase-independent cell death --- XIAP antagonists --- XIAP-BIR3 domain --- Calocedrus formosana --- lung cancer --- yatein --- cell-cycle arrest --- xenograft --- isorhamnetin --- G2/M arrest --- ROS --- AMPK --- pancreatic cancer --- epigallocatechin-3-gallate (EGCG) --- gemcitabine --- glycolysis --- phosphofructokinase --- natural polyphenols --- anticancer activities --- molecular mechanisms --- Streptomyces --- mangrove --- anti-proliferative --- colon cancer --- epithelial mesenchymal transition --- inflammation --- malignant cancer --- natural anti-inflammatory compounds --- pro-resolving lipids --- anticancer drugs --- flavonoids --- natural compounds --- Xenopus laevis --- AOM/DSS model --- melanoma cells --- nicotine --- α9-nAChR --- PD-L1 --- STAT3 --- gigantol --- AKT --- JAK/STAT --- cancer stem cell --- tumor maintenance --- tumor density --- proteomics --- honokiol --- anticancer --- mechanism --- signalling pathway --- uterine sarcoma --- fucoidan --- isobolography --- colchicine alkaloid --- mesoporous silica nanoparticles --- targeted delivery system --- PD-1 immune checkpoint inhibitor and cancer immunotherapy --- glucose transport --- drugs --- innate immunity --- β-glucans --- nutrition --- immunotherapy --- estrogen --- estrogen receptor alpha --- polyphenols --- daidzein --- daidzein metabolites --- paclitaxel --- breast cancer cells --- obesity --- renin–angiotensin system --- eicosapentaenoic acid --- adipocyte inflammation --- olive leaf extract --- oleuropein --- Seahorse analysis --- cancer metabolism --- glycolytic markers --- Malva pseudolavatera Webb & --- Berthel. --- acute myeloid leukemia --- reactive oxygen species --- brain cancer --- gliomas --- schwannomas --- malignant tumors of the peripheral nerve sheath (MPNST) --- neurofibromas --- bioavailability --- nanoparticle-based delivery systems --- natural bioactive compound --- gallic acid --- EGFR signaling --- p53 --- EGCG --- non-coding RNAs --- anti-cancer drug --- NSCLC --- EGFR TKI --- FASN inhibitors --- resistance --- n/a --- renin-angiotensin system
Listing 1 - 5 of 5 |
Sort by
|